NCT01815359 - ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis | Biotech Hunter

Enrollment

292

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Appendix CancerColorectal Cancer

Interventions

PROCEDURE

Cytoreductive Surgery

Optimal Surgical Debulking

DRUG

HIPEC with Mitomycin-C

DRUG

EPIC with FUDR and Leucovorin

Trial Locations (9)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Consent and Follow up), Harrison

11553

Memorial Sloan Kettering Nassau (Consent and Follow up), Uniondale

11725

Memorial Sloan Kettering Commack (Consent and Follow up), Commack

63110

Washington University School of Medicine, St Louis

Unknown

University of Miami, Miami

07920

Memorial Sloan Kettering Basking Ridge (Consent and Follow up), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Consent and Follow up), Middletown

07645

Memorial Sloan Kettering Bergen (Consent and Follow up), Montvale

All Listed Sponsors

collaborator

The Cleveland Clinic

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

University of Miami

OTHER

collaborator

University of Pittsburgh Medical Center

OTHER

collaborator

Washington University School of Medicine

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER